Skip to main content


Cancer epigenomics

 Guest editor: Stephan Beck

Large-scale sequencing and high-throughput studies of a wide variety of cancers are revealing epigenomic variations, including DNA methylation and histone modifications, as well as mutations in genes involved in epigenetic regulation. These findings are providing insights into cancer initiation and progression, are allowing the identification and development of epigenetic biomarkers for diagnosis, prognosis or therapeutic response, and are revealing novel approaches and targets for therapeutic intervention. Genome Medicine presents a series of articles focusing on cancer epigenomics, with commissioned comment and review articles, and original research, featuring the latest advances and translational findings with the potential to inform new approaches for screening, diagnosis, prevention and treatment of cancer.

This collection of articles has not been sponsored and articles have undergone the journal’s standard peer-review process. The Guest Editor declares no competing interests.

  1. Research

    Comparative methylome analysis identifies new tumour subtypes and biomarkers for transformation of nephrogenic rests into Wilms tumour

    Wilms tumours (WTs) are characterised by several hallmarks that suggest epimutations such as aberrant DNA methylation are involved in tumour progression: loss of imprinting at 11p15, lack of recurrent mutation...

    Jocelyn Charlton, Richard D Williams, Neil J Sebire, Sergey Popov, Gordan Vujanic, Tasnim Chagtai, Marisa Alcaide-German, Tiffany Morris, Lee M Butcher, Paul Guilhamon, Stephan Beck and Kathy Pritchard-Jones

    Genome Medicine 2015 7:11

    Published on: 2 February 2015

  2. Review

    TET proteins and the control of cytosine demethylation in cancer

    The discovery that ten-eleven translocation (TET) proteins are α-ketoglutarate-dependent dioxygenases involved in the conversion of 5-methylcytosines (5-mC) to 5-hydroxymethylcytosine (5-hmC), 5-formylcytosine...

    Laurianne Scourzic, Enguerran Mouly and Olivier A Bernard

    Genome Medicine 2015 7:9

    Published on: 29 January 2015

  3. Research

    Assessment of patient-derived tumour xenografts (PDXs) as a discovery tool for cancer epigenomics

    The use of tumour xenografts is a well-established research tool in cancer genomics but has not yet been comprehensively evaluated for cancer epigenomics.

    Paul Guilhamon, Lee M Butcher, Nadege Presneau, Gareth A Wilson, Andrew Feber, Dirk S Paul, Moritz Schütte, Johannes Haybaeck, Ulrich Keilholz, Jens Hoffman, Mark T Ross, Adrienne M Flanagan and Stephan Beck

    Genome Medicine 2014 6:116

    Published on: 12 December 2014

  4. Review

    Enhancer alterations in cancer: a source for a cell identity crisis

    Enhancers are selectively utilized to orchestrate gene expression programs that first govern pluripotency and then proceed to highly specialized programs required for the process of cellular differentiation. W...

    Ken J Kron, Swneke D Bailey and Mathieu Lupien

    Genome Medicine 2014 6:77

    Published on: 23 September 2014

  5. Review

    Pan-cancer patterns of DNA methylation

    The comparison of DNA methylation patterns across cancer types (pan-cancer methylome analyses) has revealed distinct subgroups of tumors that share similar methylation patterns. Integration of these data with ...

    Tania Witte, Christoph Plass and Clarissa Gerhauser

    Genome Medicine 2014 6:66

    Published on: 30 August 2014

  6. Research

    Large hypomethylated blocks as a universal defining epigenetic alteration in human solid tumors

    One of the most provocative recent observations in cancer epigenetics is the discovery of large hypomethylated blocks, including single copy genes, in colorectal cancer, that correspond in location to heteroch...

    Winston Timp, Hector Corrada Bravo, Oliver G McDonald, Michael Goggins, Chris Umbricht, Martha Zeiger, Andrew P Feinberg and Rafael A Irizarry

    Genome Medicine 2014 6:61

    Published on: 26 August 2014

  7. Research

    A BRCA1-mutation associated DNA methylation signature in blood cells predicts sporadic breast cancer incidence and survival

    BRCA1 mutation carriers have an 85% risk of developing breast cancer but the risk of developing non-hereditary breast cancer is difficult to assess. Our objective is to test whether a DNA methylation (DNAme) sign...

    Shahzia Anjum, Evangelia-Ourania Fourkala, Michal Zikan, Andrew Wong, Aleksandra Gentry-Maharaj, Allison Jones, Rebecca Hardy, David Cibula, Diana Kuh, Ian J Jacobs, Andrew E Teschendorff, Usha Menon and Martin Widschwendter

    Genome Medicine 2014 6:47

    Published on: 27 June 2014

  8. Research

    Early aberrant DNA methylation events in a mouse model of acute myeloid leukemia

    Aberrant DNA methylation is frequently found in human malignancies including acute myeloid leukemia (AML). While most studies focus on later disease stages, the onset of aberrant DNA methylation events and the...

    Miriam Sonnet, Rainer Claus, Natalia Becker, Manuela Zucknick, Jana Petersen, Daniel B Lipka, Christopher C Oakes, Mindaugas Andrulis, Amelie Lier, Michael D Milsom, Tania Witte, Lei Gu, Soo-Zin Kim-Wanner, Peter Schirmacher, Michael Wulfert, Norbert Gattermann…

    Genome Medicine 2014 6:34

    Published on: 30 April 2014